Figma Shares Indicated To Open $105/$110
In a recent transaction, Grigorios Siokas, the Chief Executive Officer of Cosmos Health Inc. (NASDAQ:COSM), acquired 354,296 shares of common stock at a price of $0.5645 per share. The transaction, valued at $200,000, was executed on February 24, 2025. The purchase comes as the stock trades near its 52-week low of $0.47, having declined over 53% in the past six months. According to InvestingPro analysis, the company appears undervalued at its current market capitalization of $13 million.
This acquisition was part of a debt exchange agreement between Mr. Siokas and Cosmos Health. The shares were acquired as an exchange for a total amount of $200,000 that the company owed to Mr. Siokas. Following this transaction, Mr. Siokas now holds a total of 3,897,016 shares directly. The company generates annual revenue of $56 million but faces profitability challenges with a modest gross profit margin of 8.1%.
Cosmos Health Inc., a company based in Thessaloniki, Greece, operates in the wholesale drug and pharmaceutical sector. InvestingPro subscribers can access 10 additional key insights about COSM’s financial health and market position, along with detailed valuation metrics and growth indicators.
In other recent news, Cosmos Health Inc. has postponed its planned securities offering, initially set to proceed under its Registration Statement on Form S-1. The company is awaiting the filing of its Annual Report on Form 10-K for the fiscal year ending December 31, 2024, before moving forward with the offering. Additionally, Cosmos Health is advancing its weight management product, CCX0722, to clinical trials, with a market launch anticipated in the first half of 2026. The company is collaborating with Contract Research Organizations to finalize the technical dossier for regulatory submission.
In a significant development, Cosmos Health has filed new patent applications for treatments targeting glioma and hematologic malignancies, in collaboration with Cloudpharm and the National Hellenic Research Foundation. The company also announced a 10-year contract manufacturing agreement through its subsidiary Cana Laboratories with Provident Pharmaceuticals for the production of four pharmaceutical products. Furthermore, Cosmos Health has filed a patent application for an allergy inflammation treatment, highlighting its focus on drug repurposing using its AI-powered Cloudscreen platform.
These developments reflect Cosmos Health’s ongoing efforts in research, development, and strategic partnerships to expand its healthcare offerings. The company continues to leverage its manufacturing capabilities and global distribution network to enhance its market presence. Investors are advised to consider these recent announcements as Cosmos Health aligns its business strategies with its financial objectives.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.